Soligenix, Inc. Share Price & Technical Analysis
SNGX · $0.45 (+15.38%)
Healthcare / Biotechnology
$0.45
+15.38%
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
33% return in May, -27% avg return in past 3 year May month.
-64% return in 2026, -77% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | -8% | 0% | -75% | 33% | – | – | – | – | – | – | – | -64% |
| 25 | -18% | 0% | -4% | -9% | -5% | -35% | 93% | 15% | -61% | 36% | 7% | -19% | 0% |
| 24 | -34% | 7% | -18% | -35% | -20% | -51% | 62% | -17% | 14% | -7% | -11% | -21% | -131% |
| 23 | -8% | -53% | -34% | -19% | -56% | -2% | -11% | -29% | 17% | -14% | 109% | 0% | -100% |
| 22 | -7% | 16% | 1% | -26% | 12% | 7% | 49% | -10% | -44% | 58% | -18% | -21% | 16% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Weak
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.19M
P/E ratio
—
52W high
$6.23
52W low
$0.28
Volume
38,75,363
Beta
1.31
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Soligenix, Inc. share price today?
- Soligenix, Inc. (SNGX) last traded around $0.45 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SNGX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SNGX. Download the app for real-time alerts.
- How can I analyze Soligenix, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.